摘要
目的系统评价艾迪联合化疗药物胸腔内灌注治疗恶性胸腔积液的疗效和安全性。方法计算机检索Cochrane图书馆、EMbase、Pub Med、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP),按纳入与排除标准制订检索策略,全面收集相关随机对照试验(RCT),对纳入研究采用Rev Man 5.14统计学软件进行Meta分析。结果纳入14项RCT,共915例患者。Meta分析结果显示,治疗组近期有效率[OR=3.11,95%CI(2.33,4.15),P<0.01]、生存质量改善率[OR=3.66,95%CI(2.56,5.24),P<0.01]均优于对照组,差异有统计学意义;治疗组胃肠道反应、白细胞减少、肾功能异常的发生率显著低于对照组(P<0.01);治疗组胸痛、发热、肝功能异常的发生率低于对照组,但差异无统计学意义。结论艾迪联合化疗药物胸腔内灌注治疗恶性胸腔积液能提高患者的近期疗效和生存质量,降低部分毒副作用,但由于纳入研究较少,尚有待高质量、大样本的长期研究进一步验证。
Objective To systematically evaluate the efficacy and safety of intrapleural infusion of Aidi Injection combined with chemotherapeutic drugs in the treatment of malignant pleural effusion. Methods The databases of Cochrane library,EMbase,PubMed, CNKI,CBM and VIP were retrieved by computer. The retrieval strategy was formulated according to inclusion and exclusion criteria. The randomized controlled trials（RCT） on intrapleural infusion of Aidi Injection combined with chemotherapeutic drugs in the treatment of malignant pleural effusion were entirely collected. The included RCT were performed the meta analysis by adopting the RevMan 5. 14 statistical software. Results 14 RCT were included,involving 915 patients in total. The meta analysis results indicated that the treatment group was superior to the control group in the aspects of the short term effective rate [ OR=3. 11,95% CI（2. 33,4. 15）,P ﹤ 0. 01 ] and improvement rate of quality of life [ OR=3. 66,95% CI（2. 56,5. 24）,P ﹤ 0. 01 ] ,the differences were statistically significant;the inci-dence rates of gastrointestinal reactions,leucopenia and kidney dysfunction in the treatment group were significantly lower than those in the control group （ P ﹤ 0. 01 ） . The incidence rates of fever,chest pain and liver dysfunction in the treatment group were lower than those in the control group without statistical difference. Conclusion Intrapleural infusion of Aidi Injection combined with chemothera-peutic drugs can improve the short term efficacy and quality of life in the treatment of malignant pleural effusion,decreases partial tox-ic reactions and side effects,but due to few included RCT,long-term studies with high quality and large samples are needed for fur-ther validation.
出处
《中国药业》
CAS
2015年第10期29-31,共3页
China Pharmaceuticals
